Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study

Background—smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a model based on three biomarkers: bone marrow plasma cell (BMPC) percentage > 20%, free...

Descripción completa

Detalles Bibliográficos
Autores principales: Tessier, Camille, Allard, Thomas, Boudreault, Jean-Samuel, Kaedbey, Rayan, Éthier, Vincent, Fortin, Fléchère, Pavic, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161809/
https://www.ncbi.nlm.nih.gov/pubmed/34073289
http://dx.doi.org/10.3390/curroncol28030188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161809/
https://www.ncbi.nlm.nih.gov/pubmed/34073289
http://dx.doi.org/10.3390/curroncol28030188

Ejemplares similares